Overview

Response-based Treatment of High-risk Neuroblastoma

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Carboplatin
Cisplatin
Cyclophosphamide
Doxorubicin
Etoposide
Etoposide phosphate
Ifosfamide
Interleukin-2
Isophosphamide mustard
Isotretinoin
Liposomal doxorubicin